<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119573</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000672415</org_study_id>
    <secondary_id>GOG-8014</secondary_id>
    <nct_id>NCT01119573</nct_id>
  </id_info>
  <brief_title>Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer</brief_title>
  <official_title>Micro RNA's Associated With Lymph Node Metastasis in Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may&#xD;
      help doctors identify and learn more about biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study is studying at biomarkers in tissue samples from patients with&#xD;
      stage I or stage III endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To identify microRNA expression patterns associated with lymph node metastasis in&#xD;
           samples from patients with endometrial cancer.&#xD;
&#xD;
      OUTLINE: Banked tumor tissue specimens are analyzed for microRNA expression profiling by&#xD;
      microarray analysis and reverse transcriptase-PCR assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Association between microRNA expression and lymph node metastasis</measure>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed endometrioid endometrial cancer&#xD;
&#xD;
               -  Stage IA, IB, IC, or IIIC disease&#xD;
&#xD;
               -  Any grade&#xD;
&#xD;
          -  Enrolled and evaluated on GOG-0210 Molecular Staging Study of Endometrial Cancer&#xD;
&#xD;
               -  Consented to allow their specimens and clinical data to be collected and stored&#xD;
                  for future research&#xD;
&#xD;
          -  Underwent complete surgical staging, including the following:&#xD;
&#xD;
               -  Hysterectomy&#xD;
&#xD;
               -  Bilateral oophorectomy&#xD;
&#xD;
               -  Washings as well as pelvic lymphadenectomy (sampling of four left and four right&#xD;
                  pelvic lymph nodes)&#xD;
&#xD;
               -  Para-aortic lymphadenectomy (sampling of one left and one right para-aortic lymph&#xD;
                  node)&#xD;
&#xD;
          -  Sufficient high-quality frozen primary tumor for testing with ≥ 75% tumor cellularity&#xD;
             and ≤ 10% necrosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Philip J. DiSaia</name_title>
    <organization>Gynecologic Oncology Group</organization>
  </responsible_party>
  <keyword>stage I endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

